LONDON--(BUSINESS WIRE)--Technavio has been monitoring the West Nile virus therapeutics market and it is poised to grow by USD 23.46 million during 2019-2023, progressing at a CAGR of over 2% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. Although the availability of over-the-counter (OTC) therapeutics will offer immense growth opportunities, the asymptomatic nature of the disease will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The availability of over-the-counter (OTC) therapeutics has been instrumental in driving the growth of the market. However, the asymptomatic nature of the disease might hamper market growth.
West Nile Virus Therapeutics Market 2019-2023: Segmentation
West Nile Virus Therapeutics Market is segmented as below:
■ Application
■ Neuroinvasive
■ Non-neuroinvasive
■ Geography
■ North America
■ Europe
■ Asia
■ ROW
To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR32148
West Nile Virus Therapeutics Market 2019-2023: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our West Nile virus therapeutics market report covers the following areas:
■ West Nile Virus Therapeutics Market size
■ West Nile Virus Therapeutics Market trends
■ West Nile Virus Therapeutics Market industry analysis
This study identifies rising awareness as one of the prime reasons driving the West Nile virus therapeutics market growth during the next few years.
West Nile Virus Therapeutics Market 2019-2023: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the West Nile Virus Therapeutics Market, including some of the vendors such as Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Backed with competitive intelligence and benchmarking, our research reports on the West Nile Virus Therapeutics Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
West Nile Virus Therapeutics Market 2019-2023: Key Highlights
■ CAGR of the market during the forecast period 2019-2023
■ Detailed information on factors that will assist West Nile virus therapeutics market growth during the next five years
■ Estimation of the West Nile virus therapeutics market size and its contribution to the parent market
■ Predictions on upcoming trends and changes in consumer behavior
■ The growth of the West Nile virus therapeutics market
■ Analysis of the market’s competitive landscape and detailed information on vendors
■ Comprehensive details of factors that will challenge the growth of West Nile virus therapeutics market vendors
Table Of Contents :
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
■ 2.1 Preface
■ 2.2 Preface
■ 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
■ Market ecosystem
■ Market characteristics
■ Market segmentation analysis
PART 04: MARKET SIZING
■ Market definition
■ Market sizing 2018
■ Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
■ Bargaining power of buyers
■ Bargaining power of suppliers
■ Threat of new entrants
■ Threat of substitutes
■ Threat of rivalry
■ Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
■ Market segmentation by application
■ Comparison by application
■ Neuroinvasive - Market size and forecast 2018-2023
■ Non-neuroinvasive - Market size and forecast 2018-2023
■ Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
■ Geographic segmentation
■ Geographic comparison
■ North America - Market size and forecast 2018-2023
■ Europe - Market size and forecast 2018-2023
■ Asia - Market size and forecast 2018-2023
■ ROW - Market size and forecast 2018-2023
■ Key leading countries
■ Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
■ Market drivers
■ Market challenges
PART 11: MARKET TRENDS
■ Shifting epidemiology of Flaviviridae
■ Rising awareness
■ Growing risk of spreading infections via blood transfusions
PART 12: VENDOR LANDSCAPE
■ Overview
■ Landscape disruption
■ Competitive scenario
PART 13: VENDOR ANALYSIS
■ Vendors covered
■ Vendor classification
■ Market positioning of vendors
■ Aurobindo Pharma Ltd.
■ Bayer AG
■ GlaxoSmithKline Plc
■ Granules India Ltd.
■ Johnson & Johnson Services Inc.
■ Mylan NV
■ Novartis AG
■ Perrigo Co. Plc
■ Pfizer Inc.
■ Teva Pharmaceutical Industries Ltd.
PART 14: APPENDIX
■ Research methodology
■ List of abbreviations
■ Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
